Login
$TYRA
$19.74 -$0.29 (1.42%) Live

$TYRA SEC Filings

Filed On Filing
10 Nov 2026 10-Q
10 Nov 2026 8-K: Results of Operations and Financial Condition

Reported initial Phase 2 SURF302 results for oral dabogratinib in FGFR3-altered low-grade IR NMIBC patients

27 Oct 2026 SCHEDULE 13G/A
21 Sep 2026 SCHEDULE 13G
17 Sep 2026 SCHEDULE 13D/A
17 Sep 2026 Form 4: Ra Capital MANAGEMENT, L.p., Director and 4 others

Acquired 9,078,529 Pre-Funded Warrants (Right to Buy) (Open Market Purchase) ($200M)

17 Sep 2026 SCHEDULE 13G
17 Sep 2026 Form 4: Harris Todd, Director

Received 864 shares as a grant or award ($7.89K)

17 Sep 2026 Form 4: Rueb Yuliya, Vice President, Finance (PAO)

Received 2,925 shares as a grant or award ($26.7K)

17 Sep 2026 Form 4: Fuhrman Alan, Chief Financial Officer

Received 951 shares as a grant or award ($8.68K)

15 Sep 2026 8-K: Other Events

Tyra Biosciences, Inc., a Delaware corporation (the “Company”), confirms its agreement with Jefferies LLC, Guggenheim Securities, LLC, Cantor Fitzgerald & Co., Barclays Capital Inc. and each of the other Underwriters named in Schedule A ...

15 Sep 2026 424B5
14 Sep 2026 FWP
14 Sep 2026 S-3ASR
11 Sep 2026 Form 4: Verjee Rehan, Director

Bought 971.8943 shares ($20K)

09 Sep 2026 8-K: Other Events

On September 9, 2026, Tyra Biosciences, Inc. (TYRA or the Company) announced initial results from SURF302, its Phase 2 study evaluating oral dabogratinib in patients with Fibroblast Growth Factor Receptor (FGFR) 3-altered low-grade inter...

14 Aug 2026 SCHEDULE 13G/A
14 Aug 2026 SCHEDULE 13G/A
04 Aug 2026 424B5
04 Aug 2026 10-Q

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support